| Parameter |
Group A: patients with Imatinib therapy for 15 months (N=28) |
Group B: patients with Imatinib therapy for 50 months (N=28) |
| Male sex |
N=15 (53.6 %) |
N=13 (46.4 %) |
| Age (yrs)1 |
60 (33-80) |
61 (33-74) |
| Age ≥60 yrs |
N=16 (57.1 %) |
N=16 (57.1 %) |
| BMI (kg.m-2) |
27.2 (16.8-38.1) |
27.4 (16.0-40.0) |
| Other malignancies |
N=1 (3.6 %) |
N=2 (7.1 %) |
| Other cancer therapy |
N=1 (3.6 %) |
N=0 (0.0 %) |
| Cardiac problems |
N=11 (39.3 %) |
N=7 (25.0 %) |
| Stroke |
N=0 (0.0 %) |
N=1 (3.6 %) |
| Rheumatic disease |
N=5 (17.9 %) |
N=5 (17.9 %) |
| Gastrointestinal disorders |
N=7 (25.0 %) |
N=8 (28.6 %) |
| Invalidity |
N=12 (42.9 %) |
N=8 (28.6 %) |
| Rheumatic disease and/or invalidity |
N=17 (60.7 %) |
N=16 (57.1 %) |
| Prior CML treatment |
N=10 (35.7%) |
N=19 (67.9%) |
- Interferon-α
|
N=6 |
N=19 |
- Hydroxyurea
|
N=10 |
N=17 |
- Other treatment
|
N=5 |
N=11 |
Imatinib treatment (mg/day)
- Starting dose, mg/day
|
400 (200-400) |
400 (300-400) |
- Baseline dose (mg/day)
|
400 (250-800) |
400 (100-800) |
| Disease phase |
|
|
- Chronic
|
N=27 (96.4%) |
N=27 (96.4%) |
- Not applicable
|
N=1 (3.6%) |
N=1 (3.6%) |
| Sokal risk group |
|
|
- Low
|
N=7 (25.0%) |
N=9 (32.1%) |
- Intermediate
|
N=10 (35.7%) |
N=9 (32.1%) |
- High
|
N=6 (21.4%) |
N=3 (10.7%) |
- Not applicable
|
N=5 (17.9%) |
N=7 (25.0%) |
| Imatinib therapy status |
|
|
- success
|
N=21 (75.0%) |
N=25 (89.3%) |
- failure*
|
N=7 (25.0%) |
N=3 (10.7%) |
| *Reason of failure |
|
|
- Intolerance
|
N=1 |
N=1 |
- Resistance
|
N=4 |
N=1 |
- Mutation
|
N=3 |
N=0 |
- Progression
|
N=2 |
N=1 |
1Continuous variable are summarized as median supplied with min -max range (in parentheses).
Binary variables are expresses as N (%) of a respective item.
*Imatinib failure was defined as a progression to advanced phase of the disease, loss of hematologic or cytogenetic response, lack of hematologic or cytogenetic response
achievement at the defined time points, presence of Imatinib-resistant Bcr-Abl mutation, discontinuation of Imatinib treatment because of intolerance or death from any
cause, whichever came first [11]. |
